Your new experience awaits. Try the new design now and help us make it even better

PERSPECTIVE article

Front. Mol. Biosci.

Sec. Molecular Biophysics

Volume 12 - 2025 | doi: 10.3389/fmolb.2025.1676927

This article is part of the Research TopicBiophysical Insights into the Molecular Mechanisms of NeurodegenerationView all articles

Molecular Mechanisms of Amyloid Inhibition: An NMR-Driven Framework with Polyphenols as a Case Study

Provisionally accepted
Giacomo  ZucconGiacomo Zuccon1,2Aakriti  DarnalAakriti Darnal1Edoardo  LongoEdoardo Longo2Sara  D'AroncoSara D'Aronco2Emanuele  BoselliEmanuele Boselli2Patrick  OrlandoPatrick Orlando3Alberto  CecconAlberto Ceccon1*
  • 1Laimburg Research Centre, Vadena, Italy
  • 2Libera Universita di Bolzano, Bolzano, Italy
  • 3Universita Politecnica delle Marche, Ancona, Italy

The final, formatted version of the article will be published soon.

Misfolding and aggregation of intrinsically disordered proteins into amyloid fibrils are central to neurodegenerative diseases such as Parkinson's, Alzheimer's, and Huntington's. Increasing evidence suggests that transient, low-populated oligomeric intermediates, rather than mature fibrils, are key cytotoxic species. Natural polyphenols have shown promise as amyloid inhibitors, though their mechanisms of action remain unclear due to the complexity of early aggregation. This perspective explores how solution-state NMR can quantitatively assess inhibitor mechanisms. Building on recent literature elucidating the aggregation mechanisms of the huntingtin exon 1 protein (httex1), responsible for Huntington's disease, we propose a kinetic framework that integrates early reversible oligomerization with downstream fibril formation and models the impact of small-molecule binding at distinct stages of the pathway. We show that monomer sequestration and inhibition of elongation-competent nuclei produce distinct aggregation profiles, resolvable through global fitting of NMR and kinetic data. This mechanistic insight enables classification of inhibitors by target stage—monomeric, oligomeric, or fibrillar—and demonstrates how polyphenols serve as a biologically relevant case study for applying this general NMR-driven framework to the design of small-molecule amyloid inhibitors.

Keywords: amyloid aggregation, intrinsically disordered proteins, Polyphenols, solution-state NMR spectroscopy, kinetic modeling, Protein aggregation inhibitors, OligomericIntermediates, Huntington's disease

Received: 31 Jul 2025; Accepted: 26 Aug 2025.

Copyright: © 2025 Zuccon, Darnal, Longo, D'Aronco, Boselli, Orlando and Ceccon. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Alberto Ceccon, Laimburg Research Centre, Vadena, Italy

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.